Drug intelligence / Profile preview

vonoprazan + amoxicillin + doxycycline + bismuth

Development stage: Unknown
Lead developer: Phathom Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A quadruple therapy regimen used for Helicobacter pylori (H. pylori) eradication. It combines vonoprazan (a potassium-competitive acid blocker that decreases stomach acid production), amoxicillin (an antibiotic that kills bacteria or prevents their growth), doxycycline (a tetracycline antibiotic with lower toxicity than other tetracyclines), and bismuth (usually in the form of colloidal bismuth tartrate or bismuth subsalicylate). This combination represents an evolution in H. pylori treatment approaches, particularly for patients who may have renal insufficiency or cannot tolerate standard tetracycline.

Targets

Bacterial RibosomePBP (Penicillin-binding protein family)ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on vonoprazan + amoxicillin + doxycycline + bismuth.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vonoprazan + amoxicillin + doxycycline + bismuth.